These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35576048)

  • 41. Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trials.
    Hoffmann-Vold AM; Volkmann ER; Allanore Y; Assassi S; de Vries-Bouwstra JK; Smith V; Tschoepe I; Loaiza L; Kanakapura M; Distler O
    Lancet Rheumatol; 2022 Oct; 4(10):e679-e687. PubMed ID: 38265966
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease.
    Allanore Y; Khanna D; Smith V; Aringer M; Hoffmann-Vold AM; Kuwana M; Merkel PA; Stock C; Sambevski S; Denton CP;
    Rheumatology (Oxford); 2024 Mar; 63(3):639-647. PubMed ID: 37294870
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSIS® randomized trials.
    Azuma A; Taniguchi H; Inoue Y; Kondoh Y; Ogura T; Homma S; Fujimoto T; Sakamoto W; Sugiyama Y; Nukiwa T
    Respirology; 2017 May; 22(4):750-757. PubMed ID: 27997064
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Weight loss and outcomes in subjects with progressive pulmonary fibrosis: data from the INBUILD trial.
    Kreuter M; Bendstrup E; Jouneau S; Maher TM; Inoue Y; Miede C; Lievens D; Crestani B
    Respir Res; 2023 Mar; 24(1):71. PubMed ID: 36894966
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSCIS trial.
    Azuma A; Chung L; Behera D; Chung M; Kondoh Y; Ogura T; Okamoto M; Swarnakar R; Zeng X; Zou H; Meng X; Gahlemann M; Alves M; Kuwana M;
    Respir Investig; 2021 Mar; 59(2):252-259. PubMed ID: 33223487
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases.
    Brown KK; Inoue Y; Flaherty KR; Martinez FJ; Cottin V; Bonella F; Cerri S; Danoff SK; Jouneau S; Goeldner RG; Schmidt M; Stowasser S; Schlenker-Herceg R; Wells AU
    Respirology; 2022 Apr; 27(4):294-300. PubMed ID: 35224814
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of nintedanib on health-related quality of life in Japanese patients with progressive fibrosing interstitial lung diseases: A subset analysis of the INBUILD trial.
    Inoue Y; Kitamura H; Okamoto M; Ogura T; Nishioka Y; Kuwana M; Taniguchi A; Ito T; Rohr KB; Suda T
    Respir Investig; 2024 Jul; 62(4):589-596. PubMed ID: 38692040
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities.
    Glaspole I; Bonella F; Bargagli E; Glassberg MK; Caro F; Stansen W; Quaresma M; Orsatti L; Bendstrup E
    Respir Res; 2021 Apr; 22(1):125. PubMed ID: 33902584
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSCIS trial.
    Kuwana M; Ogura T; Makino S; Homma S; Kondoh Y; Saito A; Ugai H; Gahlemann M; Takehara K; Azuma A
    Mod Rheumatol; 2021 Jan; 31(1):141-150. PubMed ID: 32243207
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis.
    Kreuter M; Costabel U; Richeldi L; Cottin V; Wijsenbeek M; Bonella F; Bendstrup E; Maher TM; Wachtlin D; Stowasser S; Kolb M
    Respiration; 2018; 95(5):317-326. PubMed ID: 29414827
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Decline in forced vital capacity as a surrogate for mortality in patients with pulmonary fibrosis.
    Maher TM; Stowasser S; Voss F; Bendstrup E; Kreuter M; Martinez FJ; Sime PJ; Stock C
    Respirology; 2023 Dec; 28(12):1147-1153. PubMed ID: 37646126
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Antifibrotic therapy - new approvals for non-IPF interstitial lung diseases].
    Markart P; Drakopanagiotakis F; Wygrecka M
    Dtsch Med Wochenschr; 2021 Feb; 146(3):181-184. PubMed ID: 33513653
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
    Distler O; Highland KB; Gahlemann M; Azuma A; Fischer A; Mayes MD; Raghu G; Sauter W; Girard M; Alves M; Clerisme-Beaty E; Stowasser S; Tetzlaff K; Kuwana M; Maher TM;
    N Engl J Med; 2019 Jun; 380(26):2518-2528. PubMed ID: 31112379
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments.
    Fleetwood K; McCool R; Glanville J; Edwards SC; Gsteiger S; Daigl M; Fisher M
    J Manag Care Spec Pharm; 2017 Mar; 23(3-b Suppl):S5-S16. PubMed ID: 28287346
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression.
    Khanna D; Maher TM; Volkmann ER; Allanore Y; Smith V; Assassi S; Kreuter M; Hoffmann-Vold AM; Kuwana M; Stock C; Alves M; Sambevski S; Denton CP
    RMD Open; 2023 Feb; 9(1):. PubMed ID: 36796874
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial.
    Assassi S; Distler O; Allanore Y; Ogura T; Varga J; Vettori S; Crestani B; Voss F; Alves M; Stowasser S; Maher TM;
    ACR Open Rheumatol; 2022 Oct; 4(10):837-844. PubMed ID: 35852465
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume.
    Kolb M; Richeldi L; Behr J; Maher TM; Tang W; Stowasser S; Hallmann C; du Bois RM
    Thorax; 2017 Apr; 72(4):340-346. PubMed ID: 27672117
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
    Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
    Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
    Paterniti MO; Bi Y; Rekić D; Wang Y; Karimi-Shah BA; Chowdhury BA
    Ann Am Thorac Soc; 2017 Sep; 14(9):1395-1402. PubMed ID: 28388260
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis.
    Kreuter M; Del Galdo F; Miede C; Khanna D; Wuyts WA; Hummers LK; Alves M; Schoof N; Stock C; Allanore Y
    Arthritis Res Ther; 2022 Jan; 24(1):19. PubMed ID: 35012623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.